

PRESS RELEASE

June 18, 2018

Nichi-Iko Pharmaceutical Co., Ltd.

Lupin Limited

Kyowa Pharmaceutical Industry Co., Ltd.

Etanercept BS Licensing Agreement

Nichi-Iko Pharmaceutical Co., Ltd. (headquarters: Toyama City, Toyama Prefecture; President and CEO Yuichi Tamura; hereinafter, Nichi-Iko), Lupin Limited (headquarters: Mumbai, India; hereinafter, Lupin) and its Japanese subsidiary Kyowa Pharmaceutical Industry Co., Ltd. (headquarters: Kita Ward, Osaka; President and Representative Director Ray Tsunoda; hereinafter, Kyowa) concluded an agreement on June 11th to license out to Nichi-Iko the drug Etanercept BS. This drug was developed by Lupin and Kyowa filed an application to the Pharmaceuticals and Medical Devices Agency (PMDA) for manufacturing and marketing approval on March 30th.

If Etanercept BS is approved, it will be sold as a Nichi-Iko product and Nichi-Iko will have exclusive rights to sell it. One year after its introduction, Nichi-Iko will acquire the Marketing Authorization from Kyowa.

Nichi-Iko currently sells the biosimilar product Infliximab BS for I.V. Infusion 100mg "Nichi-Iko". With the addition of Etanercept BS to its product portfolio, Nichi-Iko will be able to provide a wider range of treatment options, in particular for patients suffering from rheumatoid arthritis, which will help its efforts to contribute to patients.

Lupin and Kyowa will make further efforts to maintain the quality and stable supply of Etanercept BS to support the ongoing health of patients.

For press inquiries	
Nichi-Iko Pharmaceutical Co., Ltd. President Office TEL:076-442-7026、 FAX :076-415-8710	Lupin Limited Kyowa Pharmaceutical Industry Co., Ltd. President's Office TEL: 06-6121-6715、 FAX :06-6121-2858